Abstract Library

#3029 Adrenocortical Carcinoma Metastasic in Adult on Complete Response with EDP-M and Local Therapy: A Single Case Report

Introduction: Adrenocortical carcinoma (ACC) in adults is a rare tumor (incidence 0.7-2/1000000/year). Median overall survival is 3-4 years and five-year survival is 0-28% in metastatic disease. The only curative therapy is complete surgical resection, plus adjuvant therapy depending on poor prognostic factors (ENSAT stage III, R1 resection or Ki67>10%). Both recurrent oligometastatic disease and patients who respond to systemic treatment (ST), a radical approach with surgery or local therapy (LT) may be treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Morales Herrero R, Herrero Rivera D, Santos Fernández P, Benavent M,

Keywords: ACC, chemotherapy, mitotane, local therapy,

#3006 Teratoma with Malignant Transformation: A Case Report of a Neuroendocrine Tumor That Arises from the Bronchial Mucosa in a Mature Cystic Teratoma

Introduction: Mature cystic teratoma (MCT) is the most common type of germ cell tumor in the ovary. A malignant tumor that arises in a pre-existing mature teratoma is called teratoma with malignant transformation (TMT).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Espinola Benza M

Authors: Espinola Benza M, La Salvia A, Hernandez Sanchez L, Gallardo Gallego R, Suarez Pita D,

Keywords: Mature cystic teratoma, teratoma with malignant transformation, surgical resection,

#2972 Characteristics and Management of Paragangliomas, 10 Years Experience

Introduction: Paraganglioma (PG) is a rare extra-adrenal neuroendocrine tumor, with common sites of presentation being abdomen, and head and neck region. The majority of PGs appear to be sporadic. However, almost half of cases are associated with an inherited syndrome. The highest malignancy rates are seen in paragangliomas (PGs) associated with SDHB mutations, which are usually abdominal and secretory.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sardo E, Cameselle-Garcia S, Casteras A, Toledo R, Acosta D,

Keywords: Paraganglioma, SDHB mutations, Functioning Tumors,

#2845 Primary Tumour Resection and PRRT of NEN Stage IV - Are There Differences in Grading?

Introduction: The resection of primary tumours (PT) in patients with stage IV NEN is still a matter of debate. The resection of tumours with a low proliferation index (G1/G2) is more accepted then the resection of high proliferative tumours (G3-NET / G3-NEC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kaemmerer D, Trwznik M, Hörsch D, Baum R, Hommann M,

Keywords: Surgery, Primary tumor, PRRT, Grading,

#2782 Clinical Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Neoplasm

Introduction: Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine neoplasms (NEN) with positive effects on both progression free survival (PFS) and overall survival (OS). Only a few previous studies have investigated the effect of a second series and hence a retreatment with PRRT.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zacho M, Iversen P, Villadsen G, Arveschoug A, Grønbæk H,

Keywords: neuroendocrine tumor, gastropancreatic tumors, bronchopulmonary tumors, peptide receptor radionuclide therapy,